Chrispi, you seem to be taking on the role of investor relations for BTI, which is great.

In that role, could you tell us about what it will take for BTI to get a version of xb3 to clinical trials?  Yes, we know it is money.  But in 2+ years Rathjen has failed to create any monetizable interest in bioasis outside of some minor pre-clinical research collaborations and Chiesi.  And we have already heard that a dilutive financing to get to clinical is not being considered by the BoD.  Are we just waiting on Chiesi to reach a milestone payment while Rathjen toils in the background ?